Literature DB >> 8381742

Hepatocyte homologous beta 2-adrenergic desensitization is associated with a decrease in number of plasma membrane beta 2-adrenoceptors.

O Medina-Martínez1, J A García-Sáinz.   

Abstract

Preincubation of rat hepatocytes with isoproterenol induces homologous beta-adrenergic desensitization evidenced both in whole cells (cyclic AMP accumulation) and membranes (adenylyl cyclase activity). This desensitization is associated with and quantitatively similar to a loss of beta 2-adrenoceptors from the plasma membrane. Desensitization did not alter the affinities of isoproterenol for the [125I]iodocyanopindolol binding sites nor reduce the ability of guanine nucleotides to modulate agonist affinity, i.e., the receptors that remain in the surface of plasma membrane after desensitization (approximately 50%) retain their functional integrity. When membranes from isoproterenol-desensitized hepatocytes were treated with alkaline phosphatase, no attenuation of the desensitization was observed. Cholera toxin-catalyzed ADP-ribosylation was not decreased but rather slightly increased in membranes from desensitized cells as compared to the controls. Our data indicate that in hepatocytes, a loss of beta 2-adrenoceptors from the plasma membrane is closely associated to the homologous desensitization induced by isoproterenol.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381742     DOI: 10.1016/0922-4106(93)90020-a

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

Review 1.  Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?

Authors:  Katerina Okeke; Stephane Angers; Michel Bouvier; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

2.  Agonist-induced desensitization of human β3-adrenoceptors expressed in human embryonic kidney cells.

Authors:  Martina B Michel-Reher; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-12       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.